ClearSky MD’s LID-Monitor is being used in a study by University of York and Rui Jin Hospital in Shanghai into the treatment of people with Parkinson’s within the Chinese healthcare system.

LID-Monitor is a wearable device that monitors side-effects to medication prescribed for Parkinson’s over a 24-hour period.

These side effects (known as Dyskinesia) take the form of highly unpleasant involuntary movements that significantly reduce the patient’s quality of life and make caring for them difficult.

Without a monitoring device, such as LID-Monitor, it is extremely difficult, to gain enough information regarding the timing and severity of these side-effects, to make informed decisions on how to adjust the patient’s medication to ameliorate their condition.

Because of this, people with Parkinson’s in rural China are often under-medicated since this reduces these disruptive side-effects making their care in the family home easier.

This, of course, comes at the expense of a patient’s quality of life, as they are often left in a frozen morbid state, unable to move or communicate.

With an estimated 4.9 million people expected to be living with Parkinson’s in China by 2030, the introduction of technology to facilitate correct medication of Parkinson’s is essential to ensure a better quality of life and a sustainable medical care for those in rural and remote parts of China.

Professor Stephen Smith and his team at University of York will collaborate with Professor Guoqiang Chen, Clinical Neurologist and medical advisor at Shanghai Jiao Tong University Medical School in China on the project, which will assess how LID-Monitor can best be adapted to maximise uptake in China.

The joint project has been funded through the Engineering and Physical Sciences Research Council’s Global Challenges Research Fund allocation.